Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes

In this trial in patients with type 1 diabetes who were receiving insulin, the proportion of patients who achieved a glycated hemoglobin level lower than 7.0% and no severe hypoglycemia or diabetic ketoacidosis was larger in the sotagliflozin group than in the placebo group.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2017-12, Vol.377 (24), p.2337-2348
Hauptverfasser:	Garg, Satish K, Henry, Robert R, Banks, Phillip, Buse, John B, Davies, Melanie J, Fulcher, Gregory R, Pozzilli, Paolo, Gesty-Palmer, Diane, Lapuerta, Pablo, Simó, Rafael, Danne, Thomas, McGuire, Darren K, Kushner, Jake A, Peters, Anne, Strumph, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Blood glucose Blood pressure Diabetes Diabetes mellitus Diabetes Mellitus, Type 1 - blood Diabetes Mellitus, Type 1 - drug therapy Diabetic ketoacidosis Diabetic Ketoacidosis - epidemiology Diabetic Ketoacidosis - etiology Double-Blind Method Drug dosages Drug therapy Drug Therapy, Combination Female Glucose Glycated Hemoglobin A - analysis Glycosides - adverse effects Glycosides - therapeutic use Hemoglobin Humans Hypoglycemia Hypoglycemia - chemically induced Hypoglycemic Agents - adverse effects Hypoglycemic Agents - therapeutic use Insulin Insulin - adverse effects Insulin - therapeutic use Intention to Treat Analysis Ketoacidosis Least-Squares Analysis Male Middle Aged Patient safety Pharmaceuticals Sodium Sodium-glucose cotransporter Sodium-Glucose Transport Proteins - antagonists & inhibitors Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!